RBD-ACE2 binding properties in five SARS-CoV-2 variants of concern with new perspectives in the design of pan-coronavirus peptide inhibitors-Reference-Cited by-同舟云学术

RBD-ACE2 binding properties in five SARS-CoV-2 variants of concern with new perspectives in the design of pan-coronavirus peptide inhibitors

Published:2023-02 Issue:2 Volume:86 Page:e51-e54
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Yan Fangfang,Gao Feng^ORCID

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference8 articles.

1. Structural dynamics of SARS-CoV-2 variants: a health monitoring strategy for anticipating Covid-19 outbreaks;Fantini;J Infect,2021

2. World Health Organization. COVID-19 weekly epidemiological update, 25 February 2021. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update, 2021.

3. Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations;Chen;Nucleic Acids Res,2019

4. Structural and functional basis of SARS-CoV-2 entry by using human ACE2;Wang;Cell,2020

5. Comparison of the binding characteristics of SARS-CoV and SARS-CoV-2 RBDs to ACE2 at different temperatures by MD simulations;Yan;Brief Bioinform,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Omicron Variants Enhance Anchored Recognition of TMEM106B: A New Pathway for SARS-CoV-2 Cellular Invasion;The Journal of Physical Chemistry Letters;2024-01-11

2. Investigation of escape mechanisms of SARS-CoV-2 Omicron sub-lineages and exploration of potential antibodies for XBB.1;Journal of Infection;2023-10

3. A metagenomic survey on Solanum tuberosum virome revealed environmental contamination of a laboratory-developed strain of SARS-CoV-2;2023-01-17

4. Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions;Heliyon;2023-01